ABBVIE INC (ABBV)
US00287Y1091 - Common Stock
Is AbbVie Stock a Buy?
2 Excellent Dividend Stocks to Buy on the Dip
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Santa Claus will soon be on his way delivering presents to kids around the world. Three Motley Fool contributors think they've identified fantastic stocks that could be in a good position to benefit from a Santa Claus rally. Here's why they chose AbbVie (NYSE: ABBV), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX).
2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond
Noteworthy Tuesday Option Activity: ABBV, SLQT, TTD
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These companies have ingrained competitive advantages in an evergreen industry backed by decades of dividend growth.
Neurocrine Wins FDA Approval For Genetic Disorder Drug
The company can launch within a week, says Chief Executive Kyle Gano.
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
/PRNewswire/ -- AbbVie (NYSE: ABBV) and Nimble Therapeutics today announced a definitive agreement under which AbbVie will acquire Nimble, including its lead...
1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever
AbbVie Completes Acquisition of Aliada Therapeutics
/PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition,...
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging...
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from...
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating fixed-duration investigational...
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
AbbVie to Present at Citi's 2024 Global Healthcare Conference
/PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024. Scott T. Reents, executive vice...
The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys
3 Dividend Stocks That Are Screaming Buys in November
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.
AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback
AbbVie's schizophrenia treatment, courtesy of its Cerevel takeover, missed the market in two studies. But an analyst says there's still more to like.